Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. J Am Coll Cardiol HF M.PackerW.ColucciL.Fisherfor the REVIVE Heart Failure Study GroupEffect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. J Am Coll Cardiol HF12013103111  by Bahl, Ajay
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 6 2 9e6 3 56303. Armstrong PW, Gershlick AH, Goldstein P, et al., 2013.
Fibrinolysis or primary PCI in ST-segment elevation
myocardial infarction. N Engl J Med. 368: 1379e1387.
Contributed by
Sundeep Mishra
Sunil Verma
Department of Cardiology, AIIMS, New Delhi, India
E-mail address: drsundeepmishra@hotmail.com (S. Mishra)CHAMPION PHOENIX Trial. N Engl J Med 2013;368:1303e1313.
Objective: The purpose of the study was to investigate the
efficacy and safety of an intravenous ADP antagonist cangre-
lor, in the management of ischemic heart disease patients
going for PCI.
Background: Oral P2Y12 antagonist, clopidogrel has prob-
lems of slow onset of action and erratic absorption, difficulty
in administering to patients unable to swallow (intubated,
drowsy, sedated). Its long duration of action makes it more
prone to cause increased risk of bleeding, especially in emer-
gent CABG situations. Cangrelor, a new intravenous agent is
likely to be safer and efficacious in these respects.
Methods: The study was planned in 153 centers in 12
countries, randomizing 10,900 patients of Stable Angina, NSTE
ACS or STEMI, who were planned for PCI. Patients were
randomized in a double blind, double dummy manner.
Patients were randomized to either IV cangrelor or oral clo-
pidogrel 600 mg or 300 mg followed by maintenance dose
clopidogrel.
The primary efficacy endpoint (PEP) was death, myocardial
infarction (MI), Ischemia Driven Revascularization (IDR), and
stent thrombosis (ST) at 48 h as well as 30 days. The secondary
end points included individual components of the PEP as well
as stent thrombosis. Safety endpoint was GUSTO severe
bleeding at 48 h.
Results: The PEP was seen in 4.7% in cangrelor group while
5.9% in clopidogrel group OR 0.78 (0.66e0.93) p ¼ 0.005. Stent
thrombosis was 0.8% in cangrelor group while 1.4% in clopi-
dogrel group OR 0.62 (0.43e0.90) p ¼ 0.01. There was no dif-
ference in IDR, death or cardiac death. At 30 days, the benefits
of cangrelor persisted with PEP 0.85 (0.73e0.99) p ¼ 0.03; and
ST 0.68 (0.50e0.92) p ¼ 0.01.
Therewas no significant increase in GUSTOmajor bleeding
with cangrelor OR 1.5 (0.53e4.22) p ¼ 0.44 NS.
Conclusion: Intravenously administered cangrelor reduced
primary efficacy end point of death, MI, IDR, ST in a variety of
CAD patients (Stable angina, NSTEMI ACS, STEMI) by 22% in
the background of PCI compared to clopidogrel loading. This
benefit persisted over 30 days follow up. The SEP of ST was
also reduced by 38%. There was no substantial increase in
GUSTO major bleeding.1. Clinical perspective
Most new antiplatelets improve ischemic outcome at the cost
of increased bleeding. Also oral agents have a slow onset ofaction despite loading dose. Oral loading becomes a problem
when the patient is intubated, drowsy, or in shock and is
unable to take orally. The slow onset exposes the patient to a
higher ischemic event risk during PCI. Most oral agents have a
long half-life and a slow dissociation leading to increased
bleeding risk especially when considering a patient needing
emergent CABG.
Cangrelor an intravenous ADP antagonist with a short half-
life has a theoretical advantage of ‘quick inequick out’ met-
abolic profile. In this trial cangrelor showed efficacy better
than clopidogrel (PEP reduced by 22%) and stent thrombosis
reduced by 38%, the benefits persisting at 30 days follow up. At
the same time no increase in GUSTO major bleed was noted.
In this regard cangrelor joins the elite band of bivalirudin,
fondaparinux and ticagrelor which improve ischemic out-
come without compromising on safety.
Administration of cangrelor in the background of new
antiplatelets including prasugrel and ticagrelor (as loading) is
unknown. Also post cangrelor loading, which antiplatelet
would work the best as a maintenance agent is yet to be
decided. This trial confirms the hypothesis that a short acting
intravenous antiplatelet agent is safe and efficacious in the
most crucial first 48 h, persisting upto 30 days.
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Failure StudyGroup, Effect of levosimendanon the short-term
clinical course of patients with acutely decompensated heart
failure. J Am Coll Cardiol HF 1 (2013) 103e111.Objectives: The purpose of this study was to evaluate the
efficacy and safety of levosimendan, given intravenously to
patients with acutely decompensated heart failure (ADHF).
Background: Levosimendan, a positive inotropic drug with
vasodilator effects has been reported to produce favorable
effects on cardiac performance, symptoms, hospital stays and
survival in patients with ADHF. The hemodynamic effects of
levosimendan persist for many days after a 24 h infusion, due
to a long-lived active metabolite. However, it is not clear that
these hemodynamic effects translate into clinical benefits and
improved outcomes.
Methods: Two sequential trials were performed, the first to
develop a new measure of efficacy in 100 patients, and the
second to use this measure to evaluate levosimendan in an
additional 600 patients. Patients admitted with ADHF received
placebo or intravenous infusion of levosimendan for 24 h in
addition to standard treatment. The primary endpoint was a
composite that evaluated changes in clinical status during the
first 5 days after randomization.
Results: In the 600-patient trial, more levosimendan than
placebo patients improved at all 3 pre-specified time points
(6 h, 24 h, and 5 days), whereas fewer levosimendan
patients experienced clinical worsening (p ¼ 0.015). These
differences were apparent, despite more frequent
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Improvements in patient self-assessment and declines in B-
type natriuretic peptide levels with levosimendan persisted
for 5 days and were associated with reduced length of
hospital stay (p ¼ 0.009). However, levosimendan was
associated with more frequent hypotension and cardiac
arrhythmias during the infusion period and a numerically
higher risk of death (p ¼ 0.29). An excess risk of deaths in
the levosimendan group was apparent as early as 5 days;
was nominally significant at 14 days, and was largely seen
in subgroups at highest risk of death before entry into
the study (eg patients with systolic blood pressure
<100 mmHg). After 90 days, the relative risk of death
(levosimendan/placebo) was 1.9 in patients with a pre-
treatment systolic blood pressure <100 mmHg but was 1.1
in patients with a systolic blood pressure >100 mmHg.
Conclusions: In patients with ADHF, intravenous levosi-
mendan provided rapid and durable symptomatic relief.
However, levosimendan was associated with an increased
risk of adverse cardiovascular events.1. Clinical perspective
Even though positive inotropic agents have immediate ben-
eficial hemodynamic effects in patients with systolic heart
failure, they do not improve outcomes in patients with ADHF.
In fact, the use of inotropes like dopamine and milrinone is
associated with a number of adverse cardiovascular events,
and may worsen patient outcomes in the long term. Unlike
other inotropic agents, levosimendan, a calcium sensitizer,
improves myocardial contractility without causing an
increase in myocardial oxygen demand and in addition has
vasodilator properties. Because of these unique properties
levosimendan has been a promising drug and previous small
trials in patients with ADHF have reported favorable effects
on symptoms, hemodynamics and even survival. The current
REVIVE trial was a relatively large trial that tried to confirm
these findings. In this trial patients who received levosi-
mendan had improvement in symptoms and reduced hos-
pital stays as compared to those who received standard
therapy alone. Benefits of levosimendan were apparent as
early as 6 h and persisted for at least 5 days, even though the
drug was infused for only 24 h. Unfortunately, the significant
symptomatic benefit was countered by an increased risk of
serious adverse cardiovascular events. These adverse events
included hypotension, headache, atrial and ventricular
tachyarrhythmias. The most disturbing result was numeri-
cally increased (though insignificant) mortality with a hazard
ratio of 1.26 in the levosimendan group. The relative risk of
death was greatest in patients who needed inotropes the
most that is patients with a pre-treatment systolic blood
pressure <100 mmHg (relative risk 1.9). Due to serious
adverse events and trend towards increased mortality espe-
cially in sicker patients, levosimendan will only have a
limited role in the management of patients with ADHF. Based
on the current evidence, role of levosimendan should be
restricted to patients with ADHF with systolic blood pressure
>100 mmHg who remain symptomatic despite conventional
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Background: Cardiotoxicity is an important and a common
complication of cancer chemotherapeutic drugs. It may not
only be associated with significant morbidity and mortality
but also often becomes a limiting factor in adequate anti-
cancer treatment. Several pharmacological agents are being
evaluated for their efficacy in preventing cardiotoxicity of the
cancer drugs.
Material and methods:Ninety patients with hematological
malignancies undergoing chemotherapy and/or autologous
hematopoietic stem cell transplantation (HSCT) were
recruited in this study and were randomized to receive a
combination of enalapril and cardvedilol (intervention arm) or
no intervention (control arm). Comprehensive echocardiog-
raphy and cardiac magnetic resonance imaging (MRI) were
performed at baseline and at 6 months after randomization.
The primary efficacy endpoint was the absolute change from
baseline in left ventricular ejection fraction (LVEF).
Results: The mean age of the study subjects was 50  13
years. By the end of the 6 months, there was a significant fall
in LVEF in controls (3.28% absolute reduction from baseline)
but no change was seen in the intervention group. As a result,
at 6 months, LVEF was significantly lower in the control group
in comparison to the intervention group (an absolute differ-
ence of 3.1% by echocardiography and 3.4% by cardiac MRI,
p¼ 0.035 and 0.09, respectively). The beneficial effect was seen
almost exclusively in patients receiving chemotherapy alone
(absolute difference in LVEF of 6.38% at 6 months, p ¼ 0.025)
and not in those undergoing HSCT (absolute difference of
1.01%, p ¼ 0.56). In addition, compared to controls, patients in
the intervention group had a lower incidence of the combined
event of death or heart failure (6.7% vs. 22%, p ¼ 0.036) and of
death, heart failure, or a final LVEF <45% (6.7% vs. 24.4%,
p ¼ 0.02).
Conclusions: The present trial showed that a combination
of enalapril and carvedilol might prevent cardiotoxicity in
patients undergoing chemotherapy for hematological
malignancies.1. Perspective
Advancements in cancer treatment have allowed improved
prognosis and better survival in patients undergoing
